tucatinib
Selected indexed studies
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (N Engl J Med, 2020) [PMID:31825569]
- Tucatinib. (, 2006) [PMID:33226752]
- Tucatinib. (, 2012) [PMID:37782743]
_Worker-drafted node — pending editorial review._
Connections
tucatinib is a side effect of
Sources
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2020) pubmed
- Tucatinib. (2006) pubmed
- Tucatinib. (2012) pubmed
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. (2022) pubmed
- Tucatinib: First Approval. (2020) pubmed
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. (2023) pubmed
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. (2023) pubmed
- HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. (2025) pubmed
- Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer. (2024) pubmed
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. (2020) pubmed